ImmunoGen reports updated Phase Ib/II data for ovarian cancer candidate

ImmunoGen Inc. (NASDAQ:IMGN) reported updated data from the Phase Ib/II FORWARD II trial evaluating mirvetuximab soravtansine (IMGN853) to treat folate receptor 1 (FOLR1; FR-alpha)-positive, platinum-resistant epithelial ovarian cancer. The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago. ImmunoGen reported additional updates in a press release on May 16.

In 54 evaluable patients with platinum-resistant ovarian cancer who had received a median of three prior lines of therapy, mirvetuximab soravtansine plus Avastin bevacizumab led to a confirmed overall response rate (ORR) of 43% and a median progression-free survival (PFS) of 7.8 months. In a subgroup of 23 patients with "medium or high" FOLR1 expression levels, the combination led to a confirmed ORR of 48% and a median PFS of 9.9 months...